Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

34.02USD
24 Apr 2017
Change (% chg)

-- (--)
Prev Close
$34.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
602,003
52-wk High
$63.73
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics Q4 non-gaap loss per share $0.71
Tuesday, 28 Feb 2017 04:03pm EST 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces fourth quarter and full-year 2016 financial results and recent corporate developments . Q4 non-gaap loss per share $0.71 . Q4 earnings per share view $-1.33 -- Thomson Reuters I/B/E/S . Sarepta Therapeutics Inc - qtrly total revenues $5.4 million versus $1.3 million . Sarepta Therapeutics Inc says in 2017, focused on executing a successful launch of exondys 51 in US . Q4 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Sarepta - Q4 incremental loss primarily driven by expense recorded in connection with an up-front payment of $40.0 million related to license agreement with Summit Therapeutics.  Full Article

Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln
Tuesday, 21 Feb 2017 07:00am EST 

Sarepta Therapeutics Inc : Sarepta Therapeutics agrees to sale of priority review voucher for $125m . Sale of PRV provides a significant infusion of non-dilutive capital . Sarepta Therapeutics Inc - entered into an agreement to sell its rare pediatric disease priority review voucher . Sarepta Therapeutics - received prv when exondys 51 was approved by U.S. FDA for treatment of patients with duchenne muscular dystrophy amenable to exon 51 skipping .Sarepta Therapeutics Inc - as part of agreement, sarepta will receive an upfront payment of $125m upon closing of transaction.  Full Article

Sarepta Therapeutics Q3 loss per share $1.18
Thursday, 27 Oct 2016 07:00am EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments . Q3 non-gaap loss per share $0.95 excluding items . Q3 loss per share $1.18 . Sarepta Therapeutics Inc - continue to evaluate sale of priority review voucher as a potential source of non-dilutive financing .Q3 earnings per share view $-1.32 -- Thomson Reuters I/B/E/S.  Full Article

UnitedHealth spokesman confirms plan to cover Sarepta's Exondys 51
Friday, 7 Oct 2016 02:28pm EDT 

UnitedHealth Group Inc : UnitedHealth spokesman confirms plans to cover Sarepta Therapeutics Inc's muscular dystrophy drug Exondys 51. (Reporting by Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 07:05am EDT 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 07:00am EDT 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
Thursday, 29 Sep 2016 08:00am EDT 

Catabasis Pharmaceuticals Inc : Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD . Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy .Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.  Full Article

Sarepta Therapeutics reports pricing of $300 million public offering of common stock
Thursday, 22 Sep 2016 06:00pm EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces pricing of $300 million public offering of common stock . Says public offering priced at $59.75 per share . Priced public offering of an aggregate of 5.02 million shares of its common stock at a price to public of $59.75/share. .Sarepta Therapeutics announces pricing of $300 million public offering of common stock.  Full Article

Sarepta Therapeutics Q2 non-GAAP loss per share $1.19 excluding items
Tuesday, 19 Jul 2016 04:00pm EDT 

Sarepta Therapeutics Inc : No revenue was recognized for three months ended June 30, 2016 and 2015 . Sarepta Therapeutics announces second quarter 2016 financial results and recent corporate developments . Q2 non-GAAP loss per share $1.19 excluding items . Q2 loss per share $1.35 . Q2 earnings per share view $-1.19 -- Thomson Reuters I/B/E/S .Had $134.7 million in cash, cash equivalents, short-term investments and restricted cash as of June 30, 2016.  Full Article

Sarepta Therapeutics - FDA will not complete review of Eteplirsen NDA by PDUFA date
Wednesday, 25 May 2016 07:00am EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date . FDA has communicated that they will continue to work past pdufa goal date and strive to complete their work in as timely a manner as possible . FDA notified co that they are continuing review and internal discussions related to our pending NDA for Eteplirsen . fda notified co that it will not be able to complete work by Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016 . Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date .Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date.  Full Article

More From Around the Web

BRIEF-Sarepta appoints Kenneth Fischbeckt to the company’s strategic and scientific advisory board

* Sarepta Therapeutics announces addition of Kenneth Fischbeck, M.D. And matthew wood M.D., Ph.D. to the company’s strategic and scientific advisory board Source text for Eikon: Further company coverage: